Most older adults are willing to take blood tests that screen for Alzheimer's disease, but a major gap exists between patient willingness and the healthcare system's ability to deliver these tests responsibly. A new study found that over 85% of healthy older adults would accept an Alzheimer's blood test if their doctor recommended it, yet nearly 84% had never even heard of these tests before . The disconnect reveals a critical challenge as these biomarker tests move from neurology clinics into primary care.

Researchers at Northwestern University surveyed more than 600 healthy older adults with an average age of 62 to understand their attitudes toward blood tests that measure beta-amyloid and tau proteins, two hallmark proteins associated with Alzheimer's disease . The FDA has cleared two blood tests for clinical use, though many others with varying accuracy levels are available for doctors to order. Andrea Russell, the psychologist who led the study, wanted to understand whether knowledge of these tests had reached patients in primary care settings.

What Do People Actually Understand About Alzheimer's Blood Tests?

The survey revealed significant knowledge gaps and misconceptions about what these tests can and cannot do. After researchers briefly explained that blood tests measure risk for Alzheimer's but don't provide a definitive diagnosis, 94.5% of participants thought offering these tests to people with memory or thinking problems in primary care was "very important" or "somewhat important" . However, understanding the actual implications of a positive result proved more complicated.

A quarter of participants believed it was "very likely" they would develop Alzheimer's if they tested positive, and over 50% thought it was "somewhat likely" . This perception doesn't match reality. A 2025 study testing more than 2,000 healthy older adults found that only 43% of those who tested positive developed Alzheimer's within the next 10 years . Even more striking, up to a third of people with positive amyloid PET scans die cognitively normal, meaning they never develop memory loss or thinking problems despite having the biological markers of disease.

"Up to a third of people with positive amyloid PET scan die cognitively normal," explained Dr. Andrea Bozoki, a neurologist and chief of the University of North Carolina at Chapel Hill's division of Memory and Cognitive Disorders.

Dr. Andrea Bozoki, Neurologist and Chief of Memory and Cognitive Disorders at University of North Carolina at Chapel Hill

This gap between test results and actual disease development is one reason neurologists typically caution against testing cognitively healthy individuals. Dr. Bozoki noted that many physicians struggle with the concept that a test's predictive value depends largely on who is being tested, not just the numbers describing the test's accuracy .

What Barriers Could Prevent Widespread Adoption in Primary Care?

The study identified several factors that would influence whether patients accept these tests and what happens after they receive results. People were more willing to take the blood test if it would inform their medical care, if insurance covered it, and if doctors provided information about it beforehand . However, significant concerns emerged about the tests themselves and their consequences.

• Test Reliability Concerns: About 35% of participants worried about whether the blood tests were accurate enough to trust, reflecting legitimate questions about the varying accuracy levels of different tests on the market.
• Social Stigma and Discrimination: Nearly 24% expressed concern about being treated differently after testing positive, a fear that touches on real workplace and social discrimination issues.
• False Positive Anxiety: Approximately 22% worried about receiving a false positive result, which could trigger unnecessary worry and medical interventions.

The emotional impact of testing positive also emerged as a significant consideration. While 87% of participants said they would be "very likely" to take steps to improve their brain health after a positive test, more than a quarter said they would be "very likely" to experience emotional distress . Other research suggests this distress is typically short-lived, but people who test positive for Alzheimer's biomarkers often don't follow through with healthy behaviors as much as they initially intend to.

How Can Primary Care Doctors Prepare for Widespread Blood Testing?

If these blood tests become routine in primary care, physicians will need significant support and training. Right now, blood tests aren't routinely used in primary care settings. Guidelines from experts convened by the Alzheimer's Association recommend their use only by neurologists, though other guidelines recommend tests that reach a certain level of accuracy for primary care use . Roche's pTau-217 test is currently cleared for use in primary care as a tool to rule out people who don't have Alzheimer's.

The challenge for primary care doctors is substantial. With limited time to speak with each patient, counseling about the potential benefits and drawbacks of these tests becomes difficult. Dr. Nathaniel Chin, a neurologist and co-director of the Wisconsin Alzheimer's Disease Research Center, recalled one patient whose doctor ordered a blood test and referred them to his neurology clinic without any guidance . The patient and family had to wait three months to see Chin to understand what the results meant.

"The health system demands too much of primary care providers. They need more time with their patients," stated Andrea Russell, the psychologist who conducted the study.

Andrea Russell, Psychologist at Northwestern University

Russell's survey showed that people clearly want information about their cognitive health, but the question remains whether the current healthcare system can provide adequate support. Doctors need training on how to explain what positive biomarkers mean, what they don't mean, and how to counsel patients about next steps. They also need to understand the limitations of these tests in cognitively healthy individuals and know when referral to a neurologist is appropriate.

As Alzheimer's blood tests continue to advance, the focus is shifting from whether these tests work to how they should be used responsibly. Patient willingness is clearly not the barrier. Instead, healthcare systems must address physician training, insurance coverage, and clear communication about what these tests can realistically predict for individual patients.